<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="pediatricmusic/PMC3330267/results/search/disease/results.xml">
  <result pre="of progressive cognitive decline, typically at the stage of AD" exact="dementia" post="(Sperling et al., 2011). The National Institute on Aging-Alzheimer’s"/>
  <result pre="thus considers that AD can be used to refer to" exact="dementia" post="stages, as well as to MCI and pre-MCI phases."/>
  <result pre="pathology (AD-P) are at increased risk of progression to AD" exact="dementia" post="(AD-D). However, the ability of the biomarkers of AD-P"/>
  <result pre="critical role in AD development, but several other mechanisms of" exact="neurodegeneration" post="have been proposed, including pro-inflammatory responses (Wyss-Coray, 2007), mitochondrial"/>
  <result pre="correlation between cerebral amyloid plaque burden and the severity of" exact="dementia" post="(Terry et al., 1991; Nagy et al., 1996; Ingelsson,"/>
  <result pre="Contrarily to what was observed for amyloid plaques, severity of" exact="dementia" post="has been strongly correlated with NFT density (in studies"/>
  <result pre="as with soluble oligomeric Aβ (Arendt, 2009). Tau deposition and" exact="neurodegeneration" post="occur in stereotyped fashion, progressing over six stages: stages"/>
  <result pre="stages V–VI, there is severe neocortical destruction and fully developed" exact="dementia" post="(Braak and Braak, 1995; Perl, 2010). Recent investigation involving"/>
  <result pre="early onset AD; (2) individuals with a family history of" exact="dementia" post="with one or more cases of early onset AD;"/>
  <result pre="brain areas (Ruitenberg et al., 2005) and suggesting that peripheral" exact="atherosclerosis" post="biomarkers can be early indicators of a subclinical phase"/>
  <result pre="severity to AD (Knopman, 2006). Similarly to hypertension, overweight and" exact="obesity" post="initiated at adulthood seem to increase the susceptibility for"/>
  <result pre="glucose tolerance have also been associated with increased odds of" exact="dementia" post="(Biessels et al., 2006; Qiu et al., 2007). The"/>
  <result pre="et al., 2007). The direct effect of glucose-mediated toxicity and" exact="hyperinsulinemia" post="on amyloid metabolism and AD neurodegenerative processes has been"/>
  <result pre="et al., 2009). Additional risk factors have been suggested, including" exact="migraine" post="(Tyas et al., 2001), high intake of saturated fat"/>
  <result pre="(Bots et al., 1998), peripheral inflammation (Engelhart et al., 2004)," exact="atrial fibrillation" post="(Duron and Hanon, 2010) and head injury (Guo et"/>
  <result pre="the levels of mental, social and physical activity and the" exact="dementia" post="risk (Wang et al., 2002; Rovio et al., 2005)."/>
  <result pre="Stern, 2006). Epidemiology AD is the most common cause of" exact="dementia" post="(Fratiglioni et al., 2000; Lobo et al., 2000). By"/>
  <result pre="North America and Western Europe exhibited the highest prevalence of" exact="dementia" post="(6.4 and 5.4%, respectively), followed by those from Latin"/>
  <result pre="Western Pacific (4.0%) and Eastern Europe (3.8–3.9%). The annual regional" exact="dementia" post="incidence rates (per 1.000 individuals) were estimated to be"/>
  <result pre="It has been calculated that the number of people with" exact="dementia" post="may rise to 81.1 million by 2040 (Ferri et"/>
  <result pre="AD pathology is more likely to be clinically expressed as" exact="dementia" post="in women than in men (Barnes et al., 2005)."/>
  <result pre="population (Arrighi et al., 2010). Diagnosis The clinical diagnosis of" exact="dementia" post="caused by AD can approach an accuracy rate of"/>
  <result pre="followed up comprehensively over time. Outside of specialized centers, AD" exact="dementia" post="is correctly diagnosed only in about 50% of affected"/>
  <result pre="was cognitive and functional decline (a requisite incorporating MCI and" exact="dementia" post="criteria) or not. There may not always be a"/>
  <result pre="AD (MCI-AD; Albert et al., 2011) and the diagnosis of" exact="dementia" post="due to AD (AD dementia; McKhann et al., 2011),"/>
  <result pre="dementia, (2) possible AD dementia, (3) probable or possible AD" exact="dementia" post="with evidence of the AD pathophysiological process. The first"/>
  <result pre="be used for research purposes only. The authors underline that" exact="dementia" post="from all causes implies the presence of cognitive decline"/>
  <result pre="disorder. According to McKhann et al. ( 2011), probable AD" exact="dementia" post="is diagnosed when the patient meets criteria for dementia"/>
  <result pre="AD dementia is diagnosed when the patient meets criteria for" exact="dementia" post="and, in addition, there is clear-cut history of worsening"/>
  <result pre="The NIA-AA workgroup recommends that the diagnosis of probable AD" exact="dementia" post="should not be applied when there is evidence of"/>
  <result pre="core features of Dementia with Lewy bodies (DLB; other than" exact="dementia" post="itself), prominent features of fronto-temporal lobar degeneration (FTLD), evidence"/>
  <result pre="According to the same workgroup, a diagnosis of possible AD" exact="dementia" post="is made when there is an atypical course, that"/>
  <result pre="may increase the certainty that the basis of the clinical" exact="dementia" post="syndrome is the AD pathophysiological process. However, the authors"/>
  <result pre="visuo-spatial areas of the occipital and parietal cortices. Primary progressive" exact="aphasia" post="(PPA) affects almost exclusively language related structures. The PCA"/>
  <result pre="early appearance (before the age of 60) of alexia with" exact="agraphia" post="(the most frequent symptoms, which occur without significant derangement"/>
  <result pre="stream of visual perception – the where stream), manifested by" exact="agraphia" post="and apraxia, and others show occipital dysfunction (involving the"/>
  <result pre="the what stream), expressed by symptoms of visual agnosia, prosopagnosia," exact="achromatopsia" post="and alexia. A third PCA group has been suggested,"/>
  <result pre="third PCA group has been suggested, consisting of patients with" exact="cortical blindness," post="caused by degeneration of the occipital primary visual cortex"/>
  <result pre="were also difficult to differentiate from CBD cases. Primary progressive" exact="aphasia" post="was first described by Mesulam as a syndrome consisting"/>
  <result pre="PPA cases than was first considered. The syndrome of primary" exact="aphasia" post="was classically divided into two distinct patterns: non-fluent aphasia"/>
  <result pre="primary aphasia was classically divided into two distinct patterns: non-fluent" exact="aphasia" post="and semantic dementia. Recently, a third pattern was proposed,"/>
  <result pre="(CBS) cases, about 40% of the patients with the non-fluent" exact="aphasia" post="syndrome and a small percentage with behavioral FTLD and"/>
  <result pre="syndrome and a small percentage with behavioral FTLD and semantic" exact="dementia" post="syndromes had AD pathology (Alladi et al., 2007). This"/>
  <result pre="of AD, symptoms characteristic of FTLD (particularly the progressive non-fluent" exact="aphasia" post="type) or CBS should not rule out this diagnosis."/>
  <result pre="visuo-spatial abilities (Hort et al., 2010). As the differentiation of" exact="dementia" post="from MCI rests on the determination of whether or"/>
  <result pre="because marked hippocampal atrophy has also been shown in fronto-temporal" exact="dementia" post="(Galton et al., 2001), dementia with Lewy bodies (DLB;"/>
  <result pre="also been shown in fronto-temporal dementia (Galton et al., 2001)," exact="dementia" post="with Lewy bodies (DLB; Barber et al., 2000), Parkinson’s"/>
  <result pre="Lewy bodies (DLB; Barber et al., 2000), Parkinson’s disease with" exact="dementia" post="(Tam et al., 2005), vascular dementia (Barber et al.,"/>
  <result pre="al., 2000), Parkinson’s disease with dementia (Tam et al., 2005)," exact="vascular dementia" post="(Barber et al., 2000) and hippocampal sclerosis (Barkhof et"/>
  <result pre="2000), Parkinson’s disease with dementia (Tam et al., 2005), vascular" exact="dementia" post="(Barber et al., 2000) and hippocampal sclerosis (Barkhof et"/>
  <result pre="FDG PET imaging in individuals with difficult-to-characterize memory loss or" exact="dementia" post="who eventually received pathologic confirmation of diagnosis. The sensitivity,"/>
  <result pre="CSF AD profile could identify patients with potential AD type" exact="dementia" post="among patients with MCI at sensitivities in the range"/>
  <result pre="In a large cross-sectional study involving patients with AD, fronto-temporal" exact="dementia" post="(FTD) and DLB, CSF concentrations of p-tau-181 discriminated between"/>
  <result pre="CSF in cases that had clinically ambiguous diagnoses, using autopsy-confirmed" exact="dementia" post="diagnosis as gold standard. AD and non-AD patients showed"/>
  <result pre="of CBD individuals, and in almost 30% of FTLD and" exact="vascular dementia" post="patients. Individuals with psychiatric diseases and with subjective memory"/>
  <result pre="CBD individuals, and in almost 30% of FTLD and vascular" exact="dementia" post="patients. Individuals with psychiatric diseases and with subjective memory"/>
  <result pre="on many aspects of the management of this form of" exact="dementia" post="with some degree of certainty (Hort et al., 2010;"/>
  <result pre="progression. The measures currently advocated to manage this form of" exact="dementia" post="involve adapting the patient’s environment and treating the patient"/>
  <result pre="parkinsonism, chest infections, ankle edema, and an increased risk of" exact="stroke" post="and death. As already stated, minimal effective doses should"/>
  <result pre="be administered earlier in the course of AD, before significant" exact="neurodegeneration" post="has occurred. Hopefully, biomarkers will allow diagnosis before a"/>
  <result pre="neurodegeneration has occurred. Hopefully, biomarkers will allow diagnosis before a" exact="dementia" post="syndrome is installed and permit testing drugs at a"/>
  <result pre="A. O’Brien J. T. ( 2000). MRI volumetric study of" exact="dementia" post="with Lewy bodies: a comparison with AD and vascular"/>
  <result pre="of dementia with Lewy bodies: a comparison with AD and" exact="vascular dementia" post=". Neurology 54, 1304– 1309 10746602 Barkhof F. Polvikoski"/>
  <result pre="dementia with Lewy bodies: a comparison with AD and vascular" exact="dementia" post=". Neurology 54, 1304– 1309 10746602 Barkhof F. Polvikoski"/>
  <result pre="Brunner E. Brayne C. Scheltens P. ( 2006). Risk of" exact="dementia" post="in diabetes mellitus: a systematic review. Lancet Neurol. 5,"/>
  <result pre="19370562 Birks J. Harvey R. J. ( 2006). Donepezil for" exact="dementia" post="due to Alzheimer’s disease. Cochrane Database Syst. Rev. 1,"/>
  <result pre="Roth M. ( 1968). The association between quantitative measures of" exact="dementia" post="and of senile change in the cerebral grey matter"/>
  <result pre="markers and risk of dementia: the Dutch vascular factors in" exact="dementia" post="study . Haemostasis 28, 216– 222 10420069 Braak H."/>
  <result pre="Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from" exact="dementia" post="with Lewy bodies and vascular cognitive impairment: a prospective"/>
  <result pre="R. Minoshima S. ( 2007). FDG-PET improves accuracy in distinguishing" exact="frontotemporal dementia" post="and Alzheimer’s disease . Brain 130( Pt 10), 2616–"/>
  <result pre="Minoshima S. ( 2007). FDG-PET improves accuracy in distinguishing frontotemporal" exact="dementia" post="and Alzheimer’s disease . Brain 130( Pt 10), 2616–"/>
  <result pre="Martinez-Lage J. Soininen H. Hofman A. ( 2000). Incidence of" exact="dementia" post="and major subtypes in Europe: a collaborative study of"/>
  <result pre="2001). Temporal lobe rating scale: application to Alzheimer’s disease and" exact="frontotemporal dementia" post=". J. Neurol. Neurosurg. Psychiatr. 70, 165– 173 10.1136/jnnp.70.2.165"/>
  <result pre="Temporal lobe rating scale: application to Alzheimer’s disease and frontotemporal" exact="dementia" post=". J. Neurol. Neurosurg. Psychiatr. 70, 165– 173 10.1136/jnnp.70.2.165"/>
  <result pre="Crystal H. Bang S. Dresner R. ( 1988). Screening for" exact="dementia" post="by memory testing. Neurology 38, 900– 903 3368071 Guo"/>
  <result pre="10.1148/radiol.10091402 20720076 Kawas C. Corrada M. ( 2006). Alzheimer’s and" exact="dementia" post="in the oldest-old: a century of challenges. Curr. Alzheimer"/>
  <result pre="and vascular risk factors at midlife and the risk of" exact="dementia" post="and Alzheimer disease . Arch. Neurol. 62, 1556– 1560"/>
  <result pre="B. Stevens J. C. ( 2001). Practice parameter: diagnosis of" exact="dementia" post="(an evidence-based review). Neurology 56, 1143– 1153 11342678 Kukull"/>
  <result pre="and Work Groups ( 1999). Rates and risk factors for" exact="dementia" post="and Alzheimer’s disease: results from EURODEM pooled analyses ."/>
  <result pre="( 2010). Added diagnostic value of CSF biomarkers in differential" exact="dementia" post="diagnosis. Neurobiol. Aging 31, 1867– 1876 10.1016/j.neurobiolaging.2008.10.017 19150153 Leung"/>
  <result pre="Martinez-Lage J. Soininen H. Hofman A. ( 2000). Prevalence of" exact="dementia" post="and major subtypes in Europe: a collaborative study of"/>
  <result pre="Weintraub S. Phelps C. H. ( 2011). The diagnosis of" exact="dementia" post="due to Alzheimer’s disease: recommendations from the National Institute"/>
  <result pre="R. L. Kuhl D. E. ( 2001). Alzheimer’s disease versus" exact="dementia" post="with Lewy bodies: cerebral metabolic distinction with autopsy confirmation"/>
  <result pre="J. Fratiglioni L. ( 2006). Heart failure and risk of" exact="dementia" post="and Alzheimer disease: a population-based cohort study . Arch."/>
  <result pre="( 2004). A diagnostic dilemma: is &quot;Alzheimer’s dementia&quot; Alzheimer’s disease," exact="vascular dementia," post="or both? Lancet Neurol. 3, 141 10.1016/S1474-4422(04)00674-X 14980525 Roselli"/>
  <result pre="2005). Leisure-time physical activity at midlife and the risk of" exact="dementia" post="and Alzheimer’s disease . Lancet Neurol. 4, 705– 711"/>
  <result pre="Flier W. M. ( 2012). Cerebrospinal fluid markers for differential" exact="dementia" post="diagnosis in a large memory clinic cohort . Neurology"/>
  <result pre="fluid biomarkers and rate of cognitive decline in very mild" exact="dementia" post="of the Alzheimer type . Arch. Neurol. 66, 638–"/>
  <result pre="Parkinson’s disease with dementia: a comparison with Alzheimer’s disease and" exact="dementia" post="with Lewy bodies . Neurology 64, 861– 865 10.1212/01.WNL.0000153070.82309.D4"/>
  <result pre="Jack C. R. Jr. ( 2011). Antemortem differential diagnosis of" exact="dementia" post="pathology using structural MRI: differential-STAND. Neuroimage 55, 522– 531"/>
 </snippets>
</snippetsTree>
